2010 In Vitro Alternatives Forum
Hotel Monaco, Old Town Alexandria, VA
October 18-19, 2010
- Program -
Day One - Monday October 18
12:00 Registration
and Poster Viewing Available
1:00 Welcome and Opening of Forum
- E. Hill,
Institute for In Vitro Sciences (IIVS)
Session I: Regulatory Challenges and Scientific
Responses
1:05 Introduction to Session I - R. Curren, IIVS
1:10
TSCA Reauthorization Overview - J. Jones, EPA
1:35
Comments on TSCA Reform:
Member of Congress - invited
S. Amundson, Humane Society
Legislative Fund (HSLF)
R. Becker, American Chemistry
Council (ACC)
D. Fratz, Consumer Specialty Products Assoc.
(CSPA)
2:15
Lessons Learned from Alternative Methods and their Validation for New
Toxicology in the 21st Century - T. Hartung, Johns Hopkins Univ/CAAT
2:40
Lessons Learned in the ToxCast High Throughput Screening Program
- R. Kavlock, EPA
3:05
QSAR Modeling of Toxicological Responses: Leveraging the Past to
Jump Start the Future - C. Yang, Altamira LLC
3:30
Coffee Break and
Poster Viewing
4:00
Update on EPA Activities on Animal Alternatives - T. Levine, EPA
4:25 A Cooperative Effort Towards a Non-animal
Testing Strategy for Specific EPA
Regulated Products - R. Curren, IIVS
4:45
FDA Informatics and Computational Safety Analysis Program - D. Benz, FDA
5:10
Closing Remarks and Questions
5:15
A New Scientific Society: American Society for Cellular and
Computational
Toxicology (ASCCT) - E. Hill, IIVS and K. Sullivan, PCRM
5:30
Cocktail Reception:
William
& Eleanor Cave Award Presented by ARDF
Day Two - Tuesday October 19
8:00
Continental Breakfast and ASCCT
Informational Meeting- Open to all Attendees
Session II: In Vitro Approaches to Identify Skin
Sensitizers
9:00
Introduction to Session II - R. Landsiedel, BASF
9:05
Translation of Allergenic Contact Dermatitis Processes in Humans to
In Vitro Test Systems - A. Gaspari, Univ. of
Maryland, Dept. of Dermatology
9:30
Application of Peptide Reactivity Assays for Screening Skin Sensitization
Potential - F. Gerberick,
The Procter & Gamble Company
9:55 ECVAM
Prevalidation Study on Skin Sensitization Alternatives: Update on
Progress - D. Basketter, DABMEB
Consulting
10:20
The COLIPA Research & Method
Development Program for Identifying &
Characterizing
Chemical Skin Sensitizers without Animal Testing
- P.
Aeby, COLIPA
10:45
Current Status of human Cell Line Activation Test
- H. Sakaguchi, Kao Corporation
11:10
ICCVAM Progress in Advancing
Alternative Safety Testing Methods for
Assessing AllergicContact Dermatitis - W. Stokes, NIEHS/ICCVAM
11:30 Poster
Viewing
12:00 Lunch
Session III: New In Vitro Approaches Utilizing 3D
Tissue Models
1:00
Introduction to Session III: A. De Smedt, Johnson & Johnson
1:05
3D Tissue Models: Their Role in 21st Century Toxicology - R Curren, IIVS
1:20
Measuring Depth
of Injury in Irritation Models
- J. Jester, UCI Department of Ophthalmology
1:45
Integrating In Vitro Models into Risk Assessment
- A. De Smedt, Johnson & Johnson
2:10
Use of 3D Models in Genotoxicity Assays - M. Aardema
2:35
Primary 3D-Aggregating Brain Cell Cultures for Neurotoxicity
and
Developmental
Neurotoxicity Testing - E. van Vliet, Johns Hopkins Univ/CAAT
3:00
In Vitro Approaches to Inhalation Toxicology
- M. Gaça, British American Tobacco
3:25
Coffee Break and Poster Viewing
Session IV: Recent Advancements from In Vitro Manufacturers
3:55
Introduction to Session IV -
Dan Bagley, Colgate-Palmolive
4:00 Developing Microfluidic Systems for Robust
In Vitro Testing Using
Human Cellsand Tissues - M. Yarmush, Hurel
Corporation
4:20 Predicting Developmental Toxicity with
Human Embryonic Stem Cells
And Metabolomics - E. Donley,
Stemina Biomarker Discovery
4:40 Screen
Early to Understand your Compound's Toxicity Profile
- J. Srinivasan, Accelrys
5:00
Close of Forum
